NCT05915299 US National OCS Heart Perfusion (OHP) Registry
| NCT ID | NCT05915299 |
| Status | Recruiting |
| Phase | — |
| Sponsor | TransMedics |
| Condition | Heart Transplant |
| Study Type | OBSERVATIONAL |
| Enrollment | 100,000 participants |
| Start Date | 2023-08-25 |
| Primary Completion | 2029-08-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 100,000 participants in total. It began in 2023-08-25 with a primary completion date of 2029-08-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This Registry is a sponsor initiated, multi-center, observational post-approval registry with independent academic oversight.
Eligibility Criteria
Inclusion Criteria: * N/A Exclusion Criteria: * N/A
Contact & Investigator
Frequently Asked Questions
Who can join the NCT05915299 clinical trial?
This trial is open to participants of all sexes, studying Heart Transplant. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05915299 currently recruiting?
Yes, NCT05915299 is actively recruiting participants. Contact the research team at rhaqqi@transmedics.com for enrollment information.
Where is the NCT05915299 trial being conducted?
This trial is being conducted at Phoenix, United States, La Jolla, United States, Palo Alto, United States, Palo Alto, United States and 11 additional locations.
Who is sponsoring the NCT05915299 clinical trial?
NCT05915299 is sponsored by TransMedics. The trial plans to enroll 100,000 participants.